论文部分内容阅读
目的观察美洛昔康对壤塘县成人大骨节病患者关节疼痛及功能改善的疗效。方法随机选取病区成人大骨节病患者50例,予美洛昔康7.5 mg qd口服1月,收集治疗前后患者关节疼痛疗效评价指标VAS及功能评价指标WOMAC评分,观察美洛昔康对成人大骨节病疼痛及功能改善的疗效,分析不同年龄段、不同性别成人大骨节病患者之间的差异。结果治疗后VAS及WOMAC疼痛评分较治疗前均有改善(P<0.05),WOMAC僵硬、生理功能评分无明显变化,不同年龄段、不同性别患者在以上疗效评价指标上差异均无统计学意义。不良反应事件发生率为12%,主要为消化道不良反应。结论美洛昔康7.5 mg qd能改善成人大骨节病患者关节疼痛症状,对关节功能及僵硬的改善不明显,不同年龄段、不同性别之间无明显差异。
Objective To observe the effect of meloxicam on joint pain and function in adults with Kashin-Beck disease in Rangtang County. Methods Fifty patients with adult Kashin-Beck disease in the ward were randomly selected and treated with meloxicam at a dose of 7.5 mg qd orally for one month. VAS scores and WOMAC scores of functional evaluation were collected before and after treatment. The effects of meloxicam on adult Sarcoidosis and improve the efficacy of pain, analysis of different age groups, different gender adult patients with Kashin-Beck disease differences. Results The scores of VAS and WOMAC after treatment were all improved (P <0.05), and the stiffness of WOMAC and the scores of physiological function did not change significantly. There was no significant difference in the above indexes between different ages and gender groups. The incidence of adverse reactions was 12%, mainly gastrointestinal adverse reactions. Conclusion Meloxicam 7.5 mg qd can improve joint pain symptoms in adult patients with Kashin-Beck disease, improve joint function and stiffness, and have no significant difference between different age groups and different sex.